Not available
ACTRN12621000245897
Treatment
Not Applicable
Charities/Societies/Foundations,Overcoming Multiple Sclerosis Foundation
Mr William Bevens
The treatment of multiple sclerosis (MS) with immunomodulatory drugs play an important role for many people with MS (PwMS) in modifying disease progression. However, many come with significant side-effects. It has long been understood that lifestyle factors can impact the progression and outcome of MS, with programs targeting lifestyle components in PwMS describing improved quality-of-life (QoL) outcomes, disability, fatigue and mental health outcomes. The effectiveness of the Overcoming MS (OMS .... Read more
MS diagnosed by a physician. Lives in Australia, New Zealand, Canada, USA or UK. Internet connection.
Previously undertaken an Overcoming Multiple Sclerosis in-person course or engaged with any related material. Self-diagnosed MS (no physician diagnosis).
No
Sample Size 35
Min. age 18 Years
Max. age No limit
Sex Both males and females
Condition category multiple sclerosis
Condition code Neurological
Intervention code Lifestyle , Treatment: Other
This is an online lifestyle education intervention. The course takes place modularly (6 modules) with key themes in each module: diet, physical activity, vitamin D and sunlight, stress, family incidence, final motivation. Each module contains narrated videos and animations, images with text, polls and quizzes. Modules are self-paced by participants, and participants can start and stop the modules at any time. Each module takes approximately 30 to 60 minutes to complete and will have access to al .... Read more
Control group Placebo
The control group is an identically structured online course with different content. The content is generic lifestyle content sourced from MS societies around the world. The goal is to replicate the generic information that many people with MS (PwMS) are exposed to through their healthcare. By including this in a parallel course as opposed to a wait-list control, the effectiveness of the course content rather than taking a course itself can be assessed.
Outcome: Feasibility, which is >40% of participants in the intervention arm, and >25% in the control arm complete 75% of the modules. These data will be measured by website analytics tool Hotjar, which provides data on traffic and engagement. Timepoint: Feasibility end-point will be analysed at 8 weeks post-intervention commencement.
yes
All IPD (after de-identification) collected during the study, not only what is published.
Data will be made available as soon as publication of the primary findings is published. There is no proposed end date for when data will no longer be available.
Any person with a valid reason to access the data, which will be at the discretion of the PI. This can include researchers but also members of the public, particularly those with MS and their families, who have an interest in this sort of research.
Any purpose.